UCB's Global Corporate Website
Welcome to UCB in the United States



Press Release: UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

• The U.S. Food and Drug Administration’s (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology
• CIMZIA Phase 3 psoriasis studies demonstrated significant and clinically meaningful improvements in biologic-naïve patients and those previously treated with biologics, with clinical benefit maintained through 48 weeks and the flexibility of two dose regimens that allow for tailored treatment1




UCB Female Execs Lead GA Healthcare Industry Groups

We are pleased to recognize two UCB leaders, Patty Fritz and Stephanie Hunter-Banks, who were recently appointed to leadership positions for Georgia healthcare industry groups: Georgia Bio and Healthcare Businesswomen’s Association (HBA), Atlanta Chapter, respectively. In support of our corporate strategy to create maximum value for patients, UCB is dedicated to encouraging diversity and inclusion. We are proud to celebrate the accomplishments of these two leaders who encourage and inspire the UCB colleagues around them.




UCB Participates on NIH Task Force

Last year, the Secretary of Health and Human Services (HHS) appointed UCB’s Kristi Lengyel, Director of U.S. Patient Advocacy, to the National Institutes of Health (NIH) Task Force on Research Specific to Pregnant and Lactating Women (PRGLAC). 



Press Release: CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study

CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study




Press Release: UCB announces BRIVIACT® (brivaracetam) now approved by FDA to treat partial-onset (focal) seizures in pediatric epilepsy patients

• BRIVIACT® (brivaracetam) CV oral formulations are approved as a monotherapy or adjunctive therapy in patients four years of age and older with partial-onset seizures.
• Approval provides pediatric epilepsy patients a treatment option which can be initiated at a therapeutic dose from day one.
• Pediatric epilepsy is the most common, serious neurological disorder among children and young adults, thought to affect nearly 470,000 children in the U.S.,1, 2
• Indication comes less than 2 years after the launch of BRIVIACT in the U.S., building on existing adult monotherapy and adjunctive therapy indications, and broadening clinical application for UCB’s newest anti-epilepsy drug.




Disease Spotlight: 5 Things to Know About Osteoporosis

By the time you finish reading the title of this post, a fragility fracture due to osteoporosis has occurred. It is estimated that a fragility fracture occurs every 3 seconds— totaling nearly 9 million fractures annually, worldwide. In the U.S. alone, fragility fractures are responsible for approximately 500,000 hospitalizations, 800,000 emergency room visits, and 180,000 nursing home placements each year.




UCB Engages Community on how Service Dogs Help People with Epilepsy

This spring, UCB engaged the Atlanta community at the 2018 Atlanta Science Festival with a booth called “How the Canine Mind Helps People with Severe Diseases.” The festival is a two-week celebration of science offering more than 100 events at locations throughout metro Atlanta. UCB participated at the expo event held in Piedmont Park on March 24. 




UCB’s Dr. Luiz Miguel Camargo, Dedicated to Finding Cures

Luiz Miguel Camargo, Ph.D., UCB’s Director of Innovation Networks, was featured in an interview as part of the Pharmaceutical Research and Manufacturers of America (PhRMA) #GOBOLDLY campaign talking about his work and dedication to advancing science to find solutions.